

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Proposed Single Technology Appraisal (STA)**

**Lapatinib for the first-line treatment of metastatic hormone-sensitive breast cancer**

**Provisional matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• GlaxoSmithKline (lapatinib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Age Concern England</li> <li>• Black Health Agency</li> <li>• Breakthrough Breast Cancer</li> <li>• Breast Cancer Campaign</li> <li>• Breast Cancer Care</li> <li>• Breast Cancer Haven</li> <li>• Breast Cancer UK</li> <li>• British Ethnic Health Awareness Foundation</li> <li>• CANCERactive</li> <li>• Cancerbackup</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer Voices</li> <li>• Chinese National Healthy Living Centre</li> <li>• Confederation of Indian Organisations</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Helen Rollason Heal Cancer Charity</li> <li>• Help the Aged</li> <li>• Macmillan Cancer Support</li> <li>• Maggie's Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Age Concern Cymru</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Cancer Care Cymru</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association for Primary Care</li> <li>• National Public Health Service for Wales</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (tamoxifen)</li> <li>• Arrow Generics (tamoxifen)</li> <li>• AstraZeneca UK (anastrozole, fulvestrant, goserelin, tamoxifen)</li> <li>• Aventis Pharma (docetaxel)</li> <li>• Bristol-Myers Squibb Pharmaceuticals (paclitaxel, megestrol acetate)</li> <li>• Cephalon UK (liposomal doxorubicin)</li> <li>• Eli Lilly &amp; Co (gemcitabine)</li> <li>• Generics (UK) (tamoxifen)</li> <li>• IVAX Pharmaceuticals UK (tamoxifen)</li> <li>• Kent Pharmaceuticals (tamoxifen)</li> <li>• Mayne Pharma (doxorubicin, paclitaxel)</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• National Cancer Alliance</li> <li>• National Council for Palliative Care</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Sue Ryder Care</li> <li>• Tenovus Cancer Information Centre</li> <li>• Women’s Health Concern</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• British Oncological Association</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Networks Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians, Medical Oncology Joint Special Committee</li> <li>• Royal College of Radiologists</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Conwy LHB</li> <li>• Department of Health</li> <li>• Portsmouth City Teaching PCT</li> <li>• Welsh Assembly Government</li> </ul>	<ul style="list-style-type: none"> <li>• Medac UK (doxorubicin)</li> <li>• Novartis Pharmaceuticals (letrozole)</li> <li>• Orion Pharma UK (toremifene)</li> <li>• Pharmacia (doxorubicin, epirubicin)</li> <li>• Roche Products (trastuzumab)</li> <li>• Rosemont Pharmaceuticals (tamoxifen)</li> <li>• Sandoz (tamoxifen)</li> <li>• Sanofi-Aventis (docetaxel)</li> <li>• Schering-Plough (liposomal doxorubicin)</li> <li>• Teva UK (tamoxifen)</li> <li>• Wockhardt UK (doxorubicin, paclitaxel tamoxifen)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Against Breast Cancer</li> <li>• Breast Cancer Hope</li> <li>• Breast Cancer Research Trust</li> <li>• Cochrane Collaboration – Cochrane Breast Cancer Group</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Pro-Cancer Research Fund</li> <li>• Research Institute for the Care of Older People</li> <li>• United Kingdom Clinical Research Network</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul>

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
	<u>Associated Public Health Groups</u> <ul style="list-style-type: none"> <li>• tbc</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.